Sign Up to like & get
recommendations!
1
Published in 2022 at "Acta Oncologica"
DOI: 10.1080/0284186x.2022.2132116
Abstract: Abstract Background Osimertinib is a recently approved third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR-T790M resistance mutations. The aim of the present meta-analysis was to investigate the…
read more here.
Keywords:
meta analysis;
osimertinib;
safety osimertinib;
patients egfr ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14819
Abstract: To retrospectively analyze the efficacy and safety of osimertinib combined with anlotinib in the treatment of advanced non‐small‐cell lung cancer (NSCLC) after drug resistance, and to explore the related factors affecting the efficacy.
read more here.
Keywords:
cancer;
non small;
safety osimertinib;
efficacy ... See more keywords